The key elements of the Model Overdose Reversal Agents Act are to: (1) remove all existing restrictions about who can receive, possess, store, transfer without cost, or administer an ORA such that any “person or entity” is eligible; (2) require specified individuals and entities to offer ORAs to individuals at increased risk of overdose; (3) require emergency access to ORAs at specified locations for use by any individual; (4) provide guidelines for ORA sales, in particular sales of non-prescription ORAs; (6) grant broad immunity to people or entities for prescribing, dispensing, giving, donating, transferring without charge, selling, or administering ORAs in the absence of gross negligence, malice, or criminal intent; (7) identify the required content for educational information about ORAs and specify when that information must be disseminated; (8) require Medicaid and other health insurance coverage for ORAs, including non-prescription ORAs, and prohibit discriminatory life and health insurance practices; and (9) create a bulk overdose reversal agent purchasing fund to assist persons and entities to fulfill requirements under the Act.

Click here, to read the Model Overdose Reversal Agents Act.

Please note that this Model Act updates and expands the Model Expanded Access to Emergency Opioid Antagonists Act, released by LAPPA in 2021.